Disease risk early
so it can be prevented
GENinCode tests provide patients and physicians with globally leading risk assessment tools to inform preventative care and treatment strategies. Our technologies combine monogenic, polygenic and clinical information to provide advanced patient risk assessment to predict cardiovascular disease and enable prevention.
Who We Are
GENinCode provides genomic testing for the prevention, diagnosis, and treatment of cardiovascular disease. Harnessing the power of both monogenic and polygenic risk assessment to combat the world’s most prevalent health problem.
Our products and technology
GENinCode technology offers physicians globally leading risk assessment tools. Our tests combine clinical algorithms and artificial intelligence (AI) to provide advanced patient risk assessment to predict disease and enable prevention.
With over 15 years research and development in cardiovascular genomics, and in collaboration with leading institutions and clinical key opinion leaders, GENinCode has amassed a deep knowledge and understanding of the interactions between a patient’s genomic profile, lifestyle, and clinical risk factors.